PAF (C16) (Synonyms: Platelet-activating Factor C-16) |
Catalog No.GC14535
One-Click Copy Product Info
|
PAF(C16) is a membrane-derived phospholipid, It is also a platelet activating factor and a ligand for PAF G protein-coupled receptor (PAFR).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 74389-68-7
Sample solution is provided at 25 µL, 10mM.
PAF(C16) is a membrane-derived phospholipid, It is also a platelet activating factor and a ligand for PAF G protein-coupled receptor (PAFR). PAF(C16) is a potent MAPK and MEK/ERK activator. PAF(C16) can induce cell exosmosis in a dose-dependent manner and improve vascular permeability. PAF(C16) inhibits Caspase-dependent cell apoptosis by activating PAFR and has anti-apoptotic effect[1-4].
PAF(C16) (10, 25, 50, and 100 μg/ml; 2 h) inhibits M. smegmatis and M. bovis BCG growth in a dose-dependent manner[2]. PAF(C16) (10 nM; 24 h) can destroy the decreased levels of IL-25 and IL-33 in cells caused by 5α-DHT [5]. 500 nM PAF(C16) increased the numbers of phenotypic Haematopoietic stem/progenitor cell (HSPC) and induced cell cycling of HSPC[6].
PAF(C16) (5 mg/kg; orally administrated every 3 days) significantly inhibited the effect of 5α-DHT on airway hyperreactivity (AHR) [4]. PAF(C16) (0.5-10 ng/kg) given as a bolus into the renal arterial circulation of pentobarbital sodium-anesthetized male Wistar rats caused systemic hypotension and produced a dose-dependent increase in renal blood flow [7].
References:
[1]. Vadas, P, Perelman, B, et,al. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J. Allergy Clin. Immunol. 131, 144–149. doi: 10.1016/j.jaci.2012.08.016
[2]. Riaz MS, Kaur A, et,al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903. doi: 10.3389/fmicb.2018.01903. PMID: 30258409; PMCID: PMC6143801.
[3]. Ryan SD, Harris CS, et,al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8. doi: 10.1194/jlr.M800263-JLR200. Epub 2008 Jun 12. PMID: 18550892.
[4]. Bögershausen N, Tsai IC, et,al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99. doi: 10.1172/JCI80102. Epub 2015 Aug 17. PMID: 26280580; PMCID: PMC4588287.
[5]. Xia T, Ma J, et,al. Androgen receptor suppresses inflammatory response of airway epithelial cells in allergic asthma through MAPK1 and MAPK14. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221121320. doi: 10.1177/09603271221121320. PMID: 35982617.
[6]. Sun Q, Zhou Y, et,al. MEK1 activation enhances the ex vivo proliferation of haematopoietic stem/progenitor cell. Cell Biochem Funct. 2022 Jan;40(1):79-89. doi: 10.1002/cbf.3677. Epub 2021 Dec 2. PMID: 34855220.
[7]. Handa RK, Strandhoy JW, et,al. Platelet-activating factor is a renal vasodilator in the anesthetized rat. Am J Physiol. 1990 Jun;258(6 Pt 2):F1504-9. doi: 10.1152/ajprenal.1990.258.6.F1504. PMID: 2360650.
|
Cell experiment [1]: |
|
|
Cell lines |
BEAS-2B cells |
|
Preparation method |
Cells were divided into five groups, including control group, TGF-β1 treated group, TGF-β1 plus 5α-DHT treated group, TGF-β1 plus chicanine (a p38 MAPK and ERK1/2 inhibitor) treated group, TGF-β1 plus 5α-DHT and PAF(C16) treated group. The treated concentration and time of drugs were 1 nM 5α-DHT for 24 h, 50 μM chicanine for 24 h, 10 nM PAF(C16) for 24 h. Chicanine and PAF(C16) were dissolved in 2 % ethanol. |
|
Reaction Conditions |
10 nM; 24 h |
|
Applications |
PAF(C16) can destroy the decreased levels of IL-25 and IL-33 in cells caused by 5α-DHT. |
|
Animal experiment [1]: |
|
|
Animal models |
Female Wistar rats (220 ± 30 g) |
|
Preparation method |
The rats were randomly divided into six groups: control group, ovalbumin(OVA) model group (OVA), vehicle treated group (OVA + vehicle), 0.5 mg/kg 5α-DHT treated group (OVA + 5α-DHT), 15 mg/kg chicanine treated group (OVA + chicanine), 5α-DHT and 5 mg/kg PAF(C16) treated group (OVA +5α-DHT + PAF(C16)). During experiments, rats were orally administrated with vehicle or 5α-DHT or chicanine or 5α-DHT plus PAF(C16) every 3 days. |
|
Dosage form |
5 mg/kg; orally administrated every 3 days |
|
Applications |
PAF(C16) significantly inhibited the effect of 5α-DHT on airway hyperreactivity (AHR). |
|
References: [1]. Xia T, Ma J,et,al. Androgen receptor suppresses inflammatory response of airway epithelial cells in allergic asthma through MAPK1 and MAPK14. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221121320. doi: 10.1177/09603271221121320. PMID: 35982617. |
|
| Cas No. | 74389-68-7 | SDF | |
| Synonyms | Platelet-activating Factor C-16 | ||
| Chemical Name | (R)-2-acetoxy-3-(hexadecyloxy)propyl (2-(trimethylammonio)ethyl) phosphate | ||
| Canonical SMILES | [O-][P@@](OCC[N+](C)(C)C)(OC[C@@H](COCCCCCCCCCCCCCCCC)OC(C)=O)=O | ||
| Formula | C26H54NO7P | M.Wt | 523.68 |
| Solubility | 10 mg/ml in DMF,10 mg/ml in DMSO,10 mg/ml in Ethanol,PBS (pH 7.2): 25 mg/ml,30 mg/ml in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL |
| 5 mM | 381.9 μL | 1.9096 mL | 3.8191 mL |
| 10 mM | 191 μL | 954.8 μL | 1.9096 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)